サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451034

デジタル定量吸入器の市場レポート：タイプ、製品、地域別、2024-2032

Digital Dose Inhaler Market Report by Type (Branded Medication, Generics Medication), Product (Metered Dose Inhaler, Dry Powder Inhaler), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
デジタル定量吸入器の市場レポート：タイプ、製品、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のデジタル定量吸入器市場規模は2023年に33億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに101億米ドルに達し、2024年から2032年の間に12.7％の成長率（CAGR）を示すと予測しています。慢性呼吸器疾患管理への注目の高まり、リアルタイム調整のための技術進歩、喘息や慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患（CRDs）の有病率の増加は、市場を推進する主な要因の一部です。

デジタル定量吸入器（DDI）は、喘息や慢性閉塞性肺疾患（COPD）のような呼吸器疾患に罹患している個人に薬剤を送達するために使用されます。DDIにはセンサーや電子機能が内蔵されており、投薬のタイミングや量を記録することができます。処方された治療ルーチンを確実に守り、患者の病気と投薬の効果をよりよく理解するのに役立ちます。ユーザーにフィードバックを提供し、テクニックを修正するのに役立つため、DDIの需要は世界中で高まっています。

現在、DDIは薬物送達における利便性と有効性の向上を提供するため、採用が増加しており、市場の成長を後押ししています。これに加えて、患者の間で効率的で効果的な吸入装置に対する需要が高まっていることも、市場の見通しを明るいものにしています。これに伴い、呼吸器系の問題を抱えやすい老年人口の間でDDIの採用が増加しており、市場の成長を後押ししています。これとは別に、DDIは治療をより透明化し、より効果的にする可能性があるため、DDIの利用が増加しており、市場の成長に寄与しています。さらに、DDIに人工知能（AI）を統合することで、薬の使用状況の監視を強化し、患者にリアルタイムのフィードバックを提供できるようになることが、市場の成長を強化しています。さらに、個人の間で個別化された医薬品への注目が高まっていることも、市場の成長を支えています。

デジタル定量吸入器の市場動向と促進要因

慢性呼吸器疾患の有病率の増加

世界中の大衆の間で喘息や慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患（CRDs）の有病率が上昇していることが、市場の成長に寄与しています。また、呼吸器疾患の管理を必要とする人々の間では、ドラッグデリバリーシステムの強化に対する需要が増加しています。これとは別に、DDIは正確な投与量を保証し、患者と医療提供者の両方に使用に関するフィードバックを提供することにより、最新のソリューションを提供し、これは前向きな市場展望を提供しています。これに伴い、収集されたデータは、治療計画の個別化、投薬レジメのアドヒアランスの向上、CRDに関連する入院の減少に役立つ可能性があります。

リアルタイム調整のための技術の進歩

様々な企業が、より充実したケアと患者の満足度を提供するために、DDIを継続的に進化させています。各社は、ヘルスケアプロバイダーに投与量カウント、アドヒアランスモニタリング、データ送信などの機能を提供しています。これに伴い、これらの機能はより良い疾病管理を促進し、治療計画のリアルタイム調整を可能にし、患者が投薬スケジュールを効果的に遵守していることを保証するため、市場の見通しは良好です。これとは別に、DDIの技術は、治療の効果にとって極めて重要な吸入技術に関するフィードバックを患者に即座に提供することができます。その結果、これらの進歩は、重度の呼吸器疾患に苦しむ患者の呼吸器ケアの質を高めています。

慢性呼吸器疾患管理への注目の高まり

個人やヘルスケアプロバイダーの間で慢性呼吸器疾患（CRD）管理への注目が高まっていることが、市場の成長に寄与しています。これに伴い、CRDのより効率的かつ効果的な管理に対する需要が増加しています。これとは別に、DDIは服薬アドヒアランスを監視し、実用的なフィードバックを提供することができ、慢性呼吸器疾患管理の広範な戦略において重要な役割を果たしています。さらに、ヘルスケアプロバイダーが患者の服薬アドヒアランスと疾患の進行についてより的確な洞察を得ることができるため、タイムリーな介入が容易になり、患者の転帰が改善する可能性があります。さらに、より良い自己管理を促進するDDIの採用が増加しており、市場の成長を後押ししています。

本レポートで扱う主な質問

  • 2023年のデジタル定量吸入器の世界市場規模は？
  • 2024～2032年のデジタル定量吸入器の世界市場成長率は？
  • 世界のデジタル定量吸入器市場を牽引する主要因は？
  • COVID-19が世界のデジタル定量吸入器市場に与えた影響は？
  • デジタル定量吸入器の世界市場のタイプ別区分は？
  • 製品別デジタル定量吸入器の世界市場内訳は？
  • デジタル定量吸入器の世界市場における主要地域は？
  • デジタル定量吸入器の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 デジタル定量吸入器の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • ブランド薬
    • 市場動向
    • 市場予測
  • ジェネリック薬
    • 市場動向
    • 市場予測

第7章 市場内訳：製品別

  • 定量吸入器
    • 市場動向
    • 市場予測
  • ドライパウダー吸入器
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • 3M Company
    • AstraZeneca plc
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals Limited
    • H&T Presspart Manufacturing Ltd.
    • Koninklijke Philips N.V.
    • Lupin Limited
    • Novartis AG
    • OPKO Health Inc.
    • Propeller Health（ResMed）
    • Sensirion AG Switzerland
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Digital Dose Inhaler Market: Major Drivers and Challenges
  • Figure 2: Global: Digital Dose Inhaler Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Digital Dose Inhaler Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Digital Dose Inhaler Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Digital Dose Inhaler Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Digital Dose Inhaler Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Digital Dose Inhaler (Branded Medication) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Digital Dose Inhaler (Branded Medication) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Digital Dose Inhaler (Generics Medication) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Digital Dose Inhaler (Generics Medication) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Digital Dose Inhaler (Metered Dose Inhaler) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Digital Dose Inhaler (Metered Dose Inhaler) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Digital Dose Inhaler (Dry Powder Inhaler) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Digital Dose Inhaler (Dry Powder Inhaler) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: North America: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: North America: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: United States: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: United States: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Canada: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Canada: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Asia-Pacific: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Asia-Pacific: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: China: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: China: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Japan: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Japan: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: India: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: India: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: South Korea: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: South Korea: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Australia: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Australia: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Indonesia: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Indonesia: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Others: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Others: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Europe: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Europe: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Germany: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Germany: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: France: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: France: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United Kingdom: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United Kingdom: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Italy: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Italy: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Spain: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Spain: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Russia: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Russia: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Latin America: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Latin America: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Brazil: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Brazil: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Mexico: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Mexico: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Middle East and Africa: Digital Dose Inhaler Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Middle East and Africa: Digital Dose Inhaler Market: Breakup by Country (in %), 2023
  • Figure 63: Middle East and Africa: Digital Dose Inhaler Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Global: Digital Dose Inhaler Industry: SWOT Analysis
  • Figure 65: Global: Digital Dose Inhaler Industry: Value Chain Analysis
  • Figure 66: Global: Digital Dose Inhaler Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Digital Dose Inhaler Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Digital Dose Inhaler Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Digital Dose Inhaler Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Digital Dose Inhaler Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Digital Dose Inhaler Market: Competitive Structure
  • Table 6: Global: Digital Dose Inhaler Market: Key Players
目次
Product Code: SR112024A3986

The global digital dose inhaler market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.1 Billion by 2032, exhibiting a growth rate (CAGR) of 12.7% during 2024-2032. The growing focus on chronic respiratory disease management, technological advancements for real time adjustments, and increasing prevalence of chronic respiratory diseases (CRDs), such as asthma and chronic obstructive pulmonary disease (COPD, are some of the major factors propelling the market.

A digital dose inhaler (DDI) is used for delivering medication to individuals suffering from respiratory ailments like asthma or chronic obstructive pulmonary disease (COPD). It comprises built-in sensors and electronic features that can record when the medication is administered and the quantity of the dose. It assists in ensuring adherence to prescribed treatment routines and allowing for a better understanding of the disease of the patient and the effectiveness of the medication. As it provides feedback to the users and helps them to correct their technique, the demand for DDI is rising across the globe.

At present, the increasing adoption of DDIs, as they offer enhanced convenience and effectiveness in medication delivery, is bolstering the growth of the market. Besides this, the growing demand for efficient and effective inhalation devices among patients is offering a positive market outlook. In line with this, the rising adoption of DDIs among the geriatric population, as they are more prone to respiratory issues, is propelling the market growth. Apart from this, the increasing utilization of DDIs, as they make treatment more transparent and potentially more effective, is contributing to the market growth. Furthermore, the integration of artificial intelligence (AI) in DDIs to enable enhanced monitoring of medication usage and provide real-time feedback to patients is strengthening the market growth. Moreover, the increasing focus on personalized medicines among individuals is supporting the market growth.

Digital Dose Inhaler Market Trends/Drivers:

Increasing prevalence of chronic respiratory diseases

The rising prevalence of chronic respiratory diseases (CRDs), such as asthma and chronic obstructive pulmonary disease (COPD), among the masses worldwide is contributing to the market growth. In addition, there is an increase in the demand for enhanced drug delivery systems among individuals requiring management of their respiratory conditions. Apart from this, DDIs offer a modern solution by ensuring accurate dosage and providing feedback on usage to both patients and healthcare providers, which is offering a positive market outlook. In line with this, the data collected can be instrumental in personalizing treatment plans, improving adherence to medication regimes, and potentially reducing hospitalizations related to CRDs.

Technological advancements for real time adjustments

Various companies are continuously advancing their DDIs to provide enhanced care and satisfaction to patients. They offer features, such as dose counting, adherence monitoring, and data transmission, to healthcare providers. In line with this, these features promote better disease management, allow for real-time adjustments to treatment plans, and ensure that patients are effectively adhering to their medication schedules, which is offering a favorable market outlook. Apart from this, the technology in DDIs can provide immediate feedback to patients on their inhalation technique, which is crucial for the effectiveness of the treatment. As a result, these advancements are enhancing the quality of respiratory care for patients suffering from severe respiratory disorders.

Growing focus on chronic respiratory disease management

The rising focus on chronic respiratory disease (CRD) management among individuals and healthcare providers is contributing to the growth of the market. In line with this, there is an increase in the demand for more efficient and effective management of CRDs. Apart from this, DDIs can monitor medication adherence and provide actionable feedback, which plays a crucial role in the broader strategy of chronic respiratory disease management. In addition, they enable healthcare providers to have better insights into patient adherence and disease progression, facilitating timely interventions and potentially better outcomes for patients. Furthermore, the rising adoption of DDIs, as they promote better self-management, is propelling the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type and product.

Breakup by Type:

Branded Medication

Generics Medication

Branded medication accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes branded medication and generics medication. According to the report, branded medication represented the largest segment. Branded medication refers to drugs that are developed and marketed by pharmaceutical companies under a proprietary name. These medications are often the first of their kind to be introduced to the market and are protected by patents, preventing other companies from selling generic versions for a certain period. The development of branded medications involves thorough research and development (R&D) activities to ensure their efficacy, safety, and quality. Pharmaceutical companies are investing significantly in (R&D) to develop new respiratory medications, which are then sold under a brand name, often at a higher price point due to the innovation and research backing them.

Breakup by Product:

Metered Dose Inhaler

Dry Powder Inhaler

Metered dose inhaler holds the largest share in the industry

A detailed breakup and analysis of the market based on the product has also been provided in the report. This includes metered dose inhaler and dry powder inhaler. According to the report, metered dose inhaler accounted for the largest market share. Metered dose inhalers (MDIs) are one of the most common types of inhalers used in respiratory therapy. They are designed to deliver a specific amount of medication to the lungs, with each actuation or press of the inhaler. MDIs consist of a pressurized canister that contains medication in a liquid or aerosol form, housed within a plastic case with a mouthpiece. When the inhaler is actuated, it releases a measured dose of medication in aerosol form for inhalation. MDIs are popular due to their portability, ease of use, and the ability to provide quick relief in acute respiratory situations. They are highly effective for delivering bronchodilators and steroids which are commonly used in the management of conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD).

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest digital dose inhaler market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the increasing adoption of advanced respiratory devices. Additionally, the presence of well-established pharmaceutical and medical device companies is offering a positive market outlook. Apart from this, the rising focus on improving respiratory care solutions is contributing to the growth of the market. In addition, increasing incidences of respiratory disorders among individuals are propelling the growth of the market.

Competitive Landscape:

Various companies are investing in research and development (R&D) activities to create DDIs with enhanced features, such as improved dose counting, adherence monitoring, and real-time feedback mechanisms, to cater to the needs of patients and healthcare providers. Apart from this, companies are engaging in collaborations and partnerships to expand their technological capabilities and market reach. In line with this, they are providing more user-friendly and effective solutions for managing respiratory diseases. Besides this, major manufacturers are working on specialized inhaler solutions that are tailored to deliver complex biologics. Furthermore, companies are engaging in marketing and awareness campaigns to educate healthcare providers and patients about the advantages of digital dose inhalers over traditional ones.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

3M Company

AstraZeneca plc

GlaxoSmithKline plc

Glenmark Pharmaceuticals Limited

H&T Presspart Manufacturing Ltd.

Koninklijke Philips N.V.

Lupin Limited

Novartis AG

OPKO Health Inc.

Propeller Health (ResMed)

Sensirion AG Switzerland

Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

In September 2020, Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd launched two digital maintenance inhalers, such as AirDuo(R) Digihaler(R) (fluticasone propionate and salmeterol) inhalation powder and ArmonAir(R) Digihaler(R) (fluticasone propionate) inhalation powder, for patients with asthma.

In February 2022, AstraZeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.

In July 2023, Lupin launched a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Key Questions Answered in This Report

  • 1. What was the size of the global digital dose inhaler market in 2023?
  • 2. What is the expected growth rate of the global digital dose inhaler market during 2024-2032?
  • 3. What are the key factors driving the global digital dose inhaler market?
  • 4. What has been the impact of COVID-19 on the global digital dose inhaler market?
  • 5. What is the breakup of the global digital dose inhaler market based on the type?
  • 6. What is the breakup of the global digital dose inhaler market based on the product?
  • 7. What are the key regions in the global digital dose inhaler market?
  • 8. Who are the key players/companies in the global digital dose inhaler market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Digital Dose Inhaler Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Branded Medication
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Generics Medication
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Metered Dose Inhaler
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Dry Powder Inhaler
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 3M Company
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 GlaxoSmithKline plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Glenmark Pharmaceuticals Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 H&T Presspart Manufacturing Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Koninklijke Philips N.V.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Lupin Limited
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 OPKO Health Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 Propeller Health (ResMed)
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
    • 13.3.11 Sensirion AG Switzerland
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
    • 13.3.12 Teva Pharmaceutical Industries Ltd.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials